Actym Therapeutics (Series A)

Funding Details
Date Award
May 20, 2025
Vertical
Biotechnology
Funding URL
View Funding Page

Company Info
Founding Year
2017
Founders
Christopher Thanos Ph.D., Laura Hix Glickman Ph.D., Amit Kumar Ph.D.
Company Description
Actym Therapeutics has developed a microbial-based immunotherapy platform called STACT (S. Typhimurium Attenuated Cancer Therapy) that specifically enriches in many types of solid tumors and not in healthy tissue, delivering multiplexed immuno-modulatory payloads directly to tumor-resident immune cells.
Market
Immunotherapy
Location
Berkeley, California, USA
Coinvestors
Boehringer Ingelheim Venture Fund, Illumina Ventures, JLo Ventures, Korea Investment Partners, Panacea Ventures

Links
Back to Home Back to Biotechnology Deals View Funding Announcement